Navigation Links
Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
Date:9/23/2010

COMPARE StudyThe COMPARE study is a physician-initiated "all-comers" trial sponsored by Maasstad Ziekenhuis of Rotterdam, the Netherlands. The study, designed to reflect real-world, everyday clinical practice, enrolled 1,800 patients in a single- center, prospective randomized (1:1) comparison of safety and efficacy of the XIENCE V™ Everolimus Eluting Stent System to the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System.  The COMPARE trial was supported in part by an Abbott grant.  All aspects of the trial were designed and conducted independent of Abbott.

About XIENCE VAbbott's market-leading XIENCE V drug eluting stent is marketed in the United States, Europe, Japan and other international markets.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.

XIENCE V is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (lesions less than or equal to 28 mm) with reference vessel diameters of 2.5 mm to 4.25 mm. Additional information about XIENCE V, including important safety information, is available online at www.xiencev.com or www.abbottvascular.com/en_US/content/document/eIFU_XienceV.pdf.

About Abbott VascularAbbott Vascular is a global leader in cardiac and vascular care with market-leading products and an industry-leading pipeline. Abbott Vascular offers a comprehensive cardiac and vascular devices portfolio, including products for coronary artery disease, vessel closure, endovascular disease, and structural heart disease.<
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
2. New Data Reinforces Safety Profile of Abbotts Market-Leading XIENCE V(R) Drug Eluting Stent
3. Abbotts XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
4. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
5. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
6. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
7. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
8. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
9. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
10. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
11. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SANTA BARBARA, Calif. , Dec. 23, 2014 ... the Junior Doctors, Association of Sierra Leone ... Sierra Leone for the treatment of local ... While a new dedicated Ebola care center was ... Ebola virus, the facility is not available for local Sierra ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2
... Par Pharmaceutical Companies, Inc. (NYSE: PRX ... products from Teva Pharmaceuticals in connection with Teva,s acquisition ... own the ANDAs of fentanyl citrate lozenges, a generic ... version of Amrix®, as well as the U.S. rights ...
... 18, 2011 Tourists visiting the "Happiest Place on ... not able to experience it. Not all guests visiting ... walk the theme parks. Some people may appear healthy ... walking for long periods of time. Conditions stemming from ...
Cached Medicine Technology:Par Pharmaceutical Acquires Three Generic Products From Teva Pharmaceuticals 2
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch ... and coolest mobile applications on the iOS, Android, and Windows ... NewsWatch, conducted the app review and shared with viewers how ... , The old saying goes, “A picture says a thousand ... can describe a single image, because each picture holds a ...
(Date:12/25/2014)... CA (PRWEB) December 25, 2014 Each ... visits and 2 million hospital admissions across the nation ... Prevention ). The CDC’s National Hospital Ambulatory Medical ... through a survey conducted in 2010. They estimated that ... visits that resulted in a primary diagnosis of broken ...
(Date:12/24/2014)... December 25, 2014 Over 700 toys, ... their local communities. That is 700 smiling little faces ... gift. Additionally over $6000 in monetary donations was given ... some of the expenses they incur through the year. ... were A Child's Haven , Shrine's Children's Hospitals, ...
Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife Donates Over 700 Toys This Year 2
... , PROVO, Utah , Jan. 19 ... announced that it will release fourth quarter financial results prior to the ... Hunt , president and chief executive officer, will host a conference call ... a.m. (EDT) . During the call, participants can expect to hear management ...
... , ANN ARBOR, Mich. , ... and MEDITECH have collaborated to offer content from the Micromedex ... Care Information System (HCIS) — Emergency Department Management, Physician Care ... one of the Micromedex clinical evidence solutions from Thomson Reuters, ...
... , ATLANTA , Jan. 19 ... of the Unit of Interventional Radiology at the European Institute ... 2010 Best Poster Award by Dr. Shaun Samuels , ... Embolization Combined with Radiofrequency Ablation for Treating Complex Hepatic Tumors. ...
... health care, particularly at the end of life, may incite ... Hopkins emeritus professor of neurology called for the start of ... month,s issue of the Journal of Medical Ethics . ... Emeritus of Pediatric Neurology and a faculty member of the ...
... infection, researchers find , TUESDAY, Jan. 19 (HealthDay News) -- ... treatment for sickle cell disease, a common genetic disorder, new ... in the Journal of Clinical Investigation , are based ... with the disease will benefit from treatment with statins. ...
... chromosome component, research shows , TUESDAY, Jan. 19 (HealthDay ... of the reasons why omega-3 fatty acids are good for ... heart disease consumed, the slower their telomeres shrank. Telomeres are ... the more times a cell divides, making them a marker ...
Cached Medicine News:Health News:Nu Skin Enterprises to Announce Fourth Quarter and Annual 2009 Results 2Health News:Micromedex CareNotes Available Within the MEDITECH Health Care Information System 2Health News:Micromedex CareNotes Available Within the MEDITECH Health Care Information System 3Health News:Orsi Awarded First Place for Procedure with Embozene(TM) Microspheres 2Health News:Reasoning through the rationing of end-of-life care 2Health News:Shedding Light on Why Omega-3 Fatty Acids May Help the Heart 2Health News:Shedding Light on Why Omega-3 Fatty Acids May Help the Heart 3
0.3% Yeast Extract, 0.3% Malt Extract, 0.5% Peptone, and 1.0% Glucose....
Tryptone is the pancreatic digest of casein used as a nitrogen source for bacteria. Ideal for general bacteriological use with a variety of microorganisms. Tryptone is guaranteed BSE-Free....
Penicillin G (1 x 10 4 units/mL and Streptomycin (10mg/mL) Solution. 100X Concentrate....
... units Penicillin/25,000 ug Streptomycin ... and Buffer products are manufactured ... and are cell culture tested ... Properties, Sterility : Neg. , ...
Medicine Products: